I agree with much that TB says above. Further more, his recounting of his investment journey (on a number of occasions) with NEU is very valuable to biotech investors in my view. A lot of money has been made by capable shareholders in biotech stocks that struggle for many years, but due to the diligence of management over many years, and off course, the quality of their science, ultimately delivers tremendous investment returns. Despite being an investor in NEU in recent times, and making good money, I am not across the role Richard Treagus played at NEU or elsewhere, but absolutely believe TB when he says that his accomplishments are "legendary". In that regard, TB is quite wrong to make a comparison with Paul Hopper's career as an executive chairman/chairman of ASX biotechs. It may well be that PH becomes a "legend" (fingers crossed) if he remains in his current IMU role, and IMU delivers an excellent deal. To date, he hasn't; the negotiation and management of the VLA/Merck deal was the responsibility of the CEO and the CFO of VLA, not the independent chairman who had very little equity in the company and little to do with the deal, but simply had the good fortune to be able to "tick off" the $500M sale as Chair of the Board. My opinion only...DYOR
IMU Price at posting:
9.3¢ Sentiment: Hold Disclosure: Held
(20min delay)